Results 121 to 130 of about 1,577,570 (335)

Statistical analysis plan for a pragmatic randomised controlled trial comparing enhanced acceptance and commitment therapy plus ( +) added to usual aftercare versus usual aftercare only, in patients living with or beyond cancer: SUrvivors' Rehabilitation Evaluation after CANcer (SURECAN) trial

Trials
Background The aim of the SURECAN trial is to evaluate a person-centred intervention, based on Acceptance and Commitment Therapy (ACT Plus ( +)), for people who have completed treatment for cancer with curative intent, but are experiencing poor quality ...
Clare Robinson, Trudie Chalder, Paul McCrone, Olivier Quintin, Evdoxia Gkaintatzi, Imran Khan, Stephanie J. C. Taylor, on behalf of the SURECAN GROUP   +7 more
doaj   +1 more source

Oncolytic Probiotics with Molecular Pili for Solid Tumor Therapy

Advanced Science, EarlyView.
This study identifies Lactobacillus rhamnosus as an intrinsic oncolytic agent that triggers tumor metabolic collapse via calcium‐dependent ROS bursts. By chemically anchoring collagen‐targeting “molecular pili” to the bacterial surface, the engineered non‐transgenic probiotic (LR@MP) achieves targeted colonization and potent solid tumor suppression ...
Haodong Ge, Chengsheng Ding, Xiao Yang, Si Gao, Changjie Yang, Yuchen Hou, Hongye Wang, Linke Bian, Hao Zhong, Yifan Qu, Luyang Zhang, Junjun Ma, Zhengwei Cai, Wenguo Cui, Minhua Zheng   +14 more
wiley   +1 more source

Effect of a Clinical Evidence Technology on Patient Skin Disease Outcomes in Primary Care: A Cluster-Randomized Controlled Trial [PDF]

, 2018
Objective: Providers’ use of clinical evidence technologies (CETs) improves their diagnosis and treatment decisions. Despite these benefits, few studies have evaluated the impact of CETs on patient outcomes. Investigators evaluated the effect of one CET,
Burke, Marianne, Littenberg, Benjamin, MD   +1 more
core   +1 more source

The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial [PDF]

, 2013
BACKGROUND: Schizophrenia is a highly heterogeneous disorder with positive and negative symptoms being characteristic manifestations of the disease. While these two symptom domains are usually construed as distinct and orthogonal, little is known about ...
Ascher-Svanum, H, Chen, L, Johnston, JA, Kinon, BJ, Marques, TR, Stauffer, V, Succop, P   +6 more
core   +2 more sources

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

How pragmatic are the randomised trials used in recommendations for control of glycosylated haemoglobin levels in type 2 diabetic patients in general practice: an application of the PRECIS II tool

Trials, 2020
Background Recommendations for good clinical practice have been reported to be difficult to apply in real life by primary care clinicians. This could be because the clinical trials at the origin of the guidelines are based on explanatory trials ...
Isabelle Ettori-Ajasse, Elise Tatin, Gordon Forbes, Sandra Eldridge, Clarisse Dibao-Dina   +4 more
doaj   +1 more source

Effective Feedback to Improve Primary Care Prescribing Safety (EFIPPS) a pragmatic three-arm cluster randomised trial:designing the intervention (ClinicalTrials.gov registration NCT01602705) [PDF]

, 2014
Peer reviewedPublisher ...
AJ Avery, AJ Avery, B Guthrie, B Guthrie, Bruce Guthrie, Christopher Robertson, CJ Armitage, D Fick, Dennis J Petrie, DM Fick, G Godin, G Jamtvedt, HA Hausenblas, I Ajzen, JJ Francis, Karen N Barnett, KF Schulz, L Albrecht, Lewis D Ritchie, M Pirmohamed, Marion Bennie, N Ivers, P Davies, P Gallagher, P Sheeran, R Foy, R Schwarzer, RL Howard, S Michie, S Michie, S Michie, SD French, Shaun Treweek, T Dreischulte, T Dreischulte, T Higashi   +35 more
core   +8 more sources

Multimodal Wearable Biosensing Meets Multidomain AI: A Pathway to Decentralized Healthcare

Advanced Science, EarlyView.
Multimodal biosensing meets multidomain AI. Wearable biosensors capture complementary biochemical and physiological signals, while cross‐device, population‐aware learning aligns noisy, heterogeneous streams. This Review distills key sensing modalities, fusion and calibration strategies, and privacy‐preserving deployment pathways that transform ...
Chenshu Liu, Haolin Fan, Minwoo Kim, Tong Zhou, Pinyi Yang, Lingdi Zhao, Yiran Wang, Ziyuan Che, Chia‐Wei Liu, Bingbing Li, Yangzhi Zhu   +10 more
wiley   +1 more source

Public perspective on potential treatment intervention harm in clinical trials—terminology and communication

Trials
Background Randomised controlled trials (RCTs) are typically designed to determine beneficial intervention effects. In addition, an important aspect of every trial is to collect data on any potential harmful effects, with the aim of ensuring that the ...
Rachel Phillips, Dongquan Bi, Beatriz Goulão, Marie Miller, Malak El-Askary, Oluyemi Fagbemi, Curie Freeborn, Maria Giammetta, Noura El Masri, Peter Flockhart, Manos Kumar, Mike Melvin, Dianne Murray, Anthony Myhill, Laila Saeid, Shanice Thomas, Graeme MacLennan, Victoria Cornelius   +17 more
doaj   +1 more source

2010 Annual Evidence Update on Critical Illness Rehabilitation [PDF]

, 2010
For this annual evidence update a detailed literature review was undertaken to retrieve any evidence published subsequent to the literature search which formed the basis for the NICE guideline.
Gibson, Vanessa, Griffiths, John, Kishen, Roop, Morris, Craig, Parker, Robert, Treacher, David   +5 more
core